Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway

• Main Authors: Donglai Chen (Author), Fuquan Zhang (Author), Jinhui Wang (Author), Hua He (Author), Shanzhou Duan (Author), Rongying Zhu (Author), Chang Chen (Author), Lichen Yin (Author), Yongbing Chen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2018-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side effects, and drug resistance, which poses critical challenges in the clinical setting. Acquired resistance of ELTN r...